ArticleTherapeutic advances in gastroenterology2026
Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vedolizumab is a monoclonal antibody approved for adults with moderately to severely active ulcerative colitis and an inadequate response/intolerance to conventional, or anti-tumor necrosis factor (TNF) treatment. Additional efficacy data for second-line vedolizumab after first-line anti-TNF treatment are required to determine its optimal position in the treatment sequence. Objectives: To evaluate efficacy and health-related quality of life (HRQoL) associated with second-line vedolizumab after first-line anti-TNF in patients with ulcerative colitis. Design: Meta-analysis. Data sources and methods: Data from randomized, placebo-controlled phase III trials (GEMINI-1 (NCT00783718) and VISIBLE-1 (NCT02611830)) were used. Patients who received second-line vedolizumab after first-line anti-TNF treatment within 5 years before trial enrollment were included. The primary outcome was clinical remission with two definitions based on the adapted Mayo score. Secondary outcomes were corticosteroid (CS)-free remission, Mayo endoscopic score (MES) ⩽1, and HRQoL (Inflammatory Bowel Disease Questionnaire and EuroQoL-5 Dimension Visual Analog Scale). Outcomes were assessed at Week 52. Efficacy of vedolizumab versus placebo was compared using fixed-effects models. Regression analyses assessed treatment effects, adjusting for disease location/duration and previous CS use. Results: Overall, 137 patients from GEMINI-1/VISIBLE-1 were included. Patient characteristics were similar across cohorts, although mean disease duration ranged from 6.6 to 9.9 years. Second-line vedolizumab was associated with a higher likelihood of achieving both definitions of clinical remission and all secondary outcomes (CS-free remission, MES ⩽1, and HRQoL) versus placebo. Regression analysis showed that patients treated with vedolizumab were 7.13-11.35 times more likely to achieve clinical remission (both definitions) versus placebo. Conclusion: Second-line vedolizumab after first-line anti-TNF treatment significantly increased the likelihood of achieving clinical remission, MES ⩽1, and improved HRQoL at Week 52 versus placebo in patients with ulcerative colitis. The small sample size, associated limitations, and heterogeneity observed in some outcomes warrant further research to strengthen these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.